This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease withdrawal symptoms while the participant undergoes a 10-day buprenorphine detoxification.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
30
Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Illicit Opioid Use as Determine by Urine Dipsticks
urine data are from those obtained during the buprenorphine taper
Time frame: 3x weekly during wks 3 and 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.